Compare Dishman Pharma with ALEMBIC PHARMA - Equitymaster

Helping You Build Wealth With Honest Research
Since 1996. Try Now

  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

DISHMAN PHARMA vs ALEMBIC PHARMA - Comparison Results

DISHMAN PHARMA     Change

Dishman Pharmaceuticals is involved in the manufacture of APIs (active pharmaceutical ingredients), intermediates, quaternary compounds and fine chemicals. Besides this, the company is a significant player in the CRAMS (Contract Research and Manufact... More

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    DISHMAN PHARMA ALEMBIC PHARMA DISHMAN PHARMA/
ALEMBIC PHARMA
 
P/E (TTM) x 25.1 15.7 159.4% View Chart
P/BV x 3.3 3.6 92.4% View Chart
Dividend Yield % 0.7 1.1 63.1%  

Financials

 DISHMAN PHARMA   ALEMBIC PHARMA
EQUITY SHARE DATA
    DISHMAN PHARMA
Mar-16
ALEMBIC PHARMA
Mar-19
DISHMAN PHARMA/
ALEMBIC PHARMA
5-Yr Chart
Click to enlarge
High Rs374664 56.4%   
Low Rs129412 31.3%   
Sales per share (Unadj.) Rs197.8208.7 94.8%  
Earnings per share (Unadj.) Rs21.231.0 68.4%  
Cash flow per share (Unadj.) Rs34.737.1 93.6%  
Dividends per share (Unadj.) Rs2.005.50 36.4%  
Dividend yield (eoy) %0.81.0 77.8%  
Book value per share (Unadj.) Rs179.9144.2 124.7%  
Shares outstanding (eoy) m80.69188.52 42.8%   
Bonus/Rights/Conversions ---  
Price / Sales ratio x1.32.6 49.3%   
Avg P/E ratio x11.917.4 68.3%  
P/CF ratio (eoy) x7.214.5 50.0%  
Price / Book Value ratio x1.43.7 37.5%  
Dividend payout %9.417.7 53.2%   
Avg Mkt Cap Rs m20,306101,461 20.0%   
No. of employees `0000.8NA-   
Total wages/salary Rs m5,3557,467 71.7%   
Avg. sales/employee Rs Th19,252.7NM-  
Avg. wages/employee Rs Th6,459.5NM-  
Avg. net profit/employee Rs Th2,064.1NM-  
INCOME DATA
Net Sales Rs m15,96139,347 40.6%  
Other income Rs m26594 282.9%   
Total revenues Rs m16,22639,441 41.1%   
Gross profit Rs m4,1038,736 47.0%  
Depreciation Rs m1,0911,152 94.6%   
Interest Rs m944184 513.0%   
Profit before tax Rs m2,3347,493 31.1%   
Minority Interest Rs m011 0.0%   
Prior Period Items Rs m1-93 -1.2%   
Extraordinary Inc (Exp) Rs m00-   
Tax Rs m6241,568 39.8%   
Profit after tax Rs m1,7115,844 29.3%  
Gross profit margin %25.722.2 115.8%  
Effective tax rate %26.720.9 127.7%   
Net profit margin %10.714.9 72.2%  
BALANCE SHEET DATA
Current assets Rs m11,01819,577 56.3%   
Current liabilities Rs m9,51714,896 63.9%   
Net working cap to sales %9.411.9 79.0%  
Current ratio x1.21.3 88.1%  
Inventory Days Days11090 123.1%  
Debtors Days Days3545 76.8%  
Net fixed assets Rs m16,30427,097 60.2%   
Share capital Rs m161377 42.8%   
"Free" reserves Rs m12,90726,811 48.1%   
Net worth Rs m14,51627,188 53.4%   
Long term debt Rs m4,1894,993 83.9%   
Total assets Rs m29,80547,778 62.4%  
Interest coverage x3.541.7 8.3%   
Debt to equity ratio x0.30.2 157.2%  
Sales to assets ratio x0.50.8 65.0%   
Return on assets %8.912.6 70.6%  
Return on equity %11.821.5 54.8%  
Return on capital %17.523.6 74.3%  
Exports to sales %24.80-   
Imports to sales %3.70-   
Exports (fob) Rs m3,956NA-   
Imports (cif) Rs m596NA-   
Fx inflow Rs m4,95219,453 25.5%   
Fx outflow Rs m6976,065 11.5%   
Net fx Rs m4,25513,388 31.8%   
CASH FLOW
From Operations Rs m2,7868,120 34.3%  
From Investments Rs m-1,529-7,556 20.2%  
From Financial Activity Rs m-941590 -159.4%  
Net Cashflow Rs m3161,153 27.4%  

Share Holding

Indian Promoters % 61.4 74.1 82.9%  
Foreign collaborators % 0.0 0.0 -  
Indian inst/Mut Fund % 3.7 2.9 127.6%  
FIIs % 12.7 9.1 139.6%  
ADR/GDR % 0.0 0.0 -  
Free float % 22.1 13.9 159.0%  
Shareholders   46,261 49,328 93.8%  
Pledged promoter(s) holding % 35.8 0.0 -  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare DISHMAN PHARMA With:   IPCA LABS  NOVARTIS  DR. DATSONS LABS  PROCTER & GAMBLE HEALTH  SANOFI INDIA  

Compare DISHMAN PHARMA With:   MYLAN (US)  ACTAVIS (US)  ADCOCK INGRAM (S. Africa)  TEVA PHARMA (Israel)  



Today's Market

Sensex Opens Flat; HDFC and TCS Top Gainers(09:30 am)

Asian share markets are higher today as Chinese and Hong Kong shares show gains. The Shanghai Composite is up 0.1% while the Hang Seng is up 0.9%

Related Views on News

ALEMBIC PHARMA Announces Quarterly Results (1QFY20); Net Profit Up 36.4% (Quarterly Result Update)

Aug 21, 2019 | Updated on Aug 21, 2019

For the quarter ended June 2019, ALEMBIC PHARMA has posted a net profit of Rs 1 bn (up 36.4% YoY). Sales on the other hand came in at Rs 9 bn (up 10.0% YoY). Read on for a complete analysis of ALEMBIC PHARMA's quarterly results.

ALEMBIC PHARMA 2018-19 Annual Report Analysis (Annual Result Update)

Jun 13, 2019 | Updated on Jun 13, 2019

Here's an analysis of the annual report of ALEMBIC PHARMA for 2018-19. It includes a full income statement, balance sheet and cash flow analysis of ALEMBIC PHARMA. Also includes updates on the valuation of ALEMBIC PHARMA.

ALEMBIC PHARMA Announces Quarterly Results (4QFY19); Net Profit Up 28.9% (Quarterly Result Update)

May 9, 2019 | Updated on May 9, 2019

For the quarter ended March 2019, ALEMBIC PHARMA has posted a net profit of Rs 1 bn (up 28.9% YoY). Sales on the other hand came in at Rs 9 bn (up 8.6% YoY). Read on for a complete analysis of ALEMBIC PHARMA's quarterly results.

ALEMBIC PHARMA 2017-18 Annual Report Analysis (Annual Result Update)

Dec 21, 2018 | Updated on Dec 21, 2018

Here's an analysis of the annual report of ALEMBIC PHARMA for 2017-18. It includes a full income statement, balance sheet and cash flow analysis of ALEMBIC PHARMA. Also includes updates on the valuation of ALEMBIC PHARMA.

ALEMBIC PHARMA Announces Quarterly Results (2QFY19); Net Profit Up 61.0% (Quarterly Result Update)

Oct 23, 2018 | Updated on Oct 23, 2018

For the quarter ended September 2018, ALEMBIC PHARMA has posted a net profit of Rs 2 bn (up 61.0% YoY). Sales on the other hand came in at Rs 11 bn (up 42.8% YoY). Read on for a complete analysis of ALEMBIC PHARMA's quarterly results.

More Views on News

Most Popular

My 3 Best Small-cap Stocks to Get Rich in this Market Rebound(Profit Hunter)

Oct 14, 2019

This is once in a decade opportunity to make a killing from smallcap rebound.

Finally, Is the Share Price of Yes Bank Ready for a Rebound?(The 5 Minute Wrapup)

Oct 7, 2019

Here's what every individual investor must know about Yes Bank...

The One Stock I Like in this Market(The 5 Minute Wrapup)

Oct 10, 2019

There are rare periods in markets when you get good quality stocks at attractive valuations. Is this one such period?

Rebound Riches Could be Yours With These Stocks(Profit Hunter)

Oct 4, 2019

The secret to multibagger is not big businesses, but great managements... Here's how to find them to make the most of once in a decade rebound opportunity.

5 Smart Money Stocks to Profit from the Market Rebound(The 5 Minute Wrapup)

Oct 11, 2019

Now is the time to put money in these 5 stocks to take advantage of the recovery in the economy and the markets.

More

Get the Indian Stock Market's
Most Profitable Ideas

How To Beat Sensex Guide 2020
Get our special report, How to Beat Sensex Nearly 3X Now!
We will never sell or rent your email id.
Please read our Terms

DISHMAN PHARMA SHARE PRICE


May 29, 2017 (Close)

TRACK DISHMAN PHARMA

  • Track your investment in DISHMAN PHARMA with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

MORE ON DISHMAN PHARMA

DISHMAN PHARMA 5-YR ANALYSIS

COMPARE DISHMAN PHARMA WITH

MARKET STATS